Company Overview of Takeda Pharmaceuticals International GmbH
Takeda Pharmaceuticals International GmbH, a pharmaceutical company, manufactures and markets patented products, branded generics, and over-the-counter products that treat patients in various therapeutic areas worldwide. It offers its products in the areas of cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine (gastrointestinal and genitourinary), and vaccines. The company also provides packaging, development, contract manufacturing, and quality control services. Takeda Pharmaceuticals International GmbH was formerly known as Nycomed International Management GmbH and changed its name to Takeda Pharmaceuticals International GmbH in Dece...
Founded in 1874
Key Executives for Takeda Pharmaceuticals International GmbH
Corporate Officer and President of Europe & Canada Business Unit
Head of Commercial Operations - Emerging Markets
Executive Vice President of Human Resources and IS/IT
Director of External Communications
Compensation as of Fiscal Year 2014.
Takeda Pharmaceuticals International GmbH Key Developments
Valeant Canada Acquires Rights to Edarbi and Edarbyclor for the Canadian Market from Takeda Pharmaceuticals International GmbH
Dec 17 14
Valeant Canada announced it has acquired the Canadian rights to Edarbi™ (azilsartan medoxomil) and Edarbyclor™ (azilsartan medoxomil and chlorthalidone), two products from Takeda Pharmaceutical International GmbH that have been approved by Health Canada, and are indicated for hypertension. The rights were acquired through a license, distribution and supply agreement between affiliates of Valeant Canada and Takeda Pharmaceutical International. The licensing of these complementary products supports Valeant Canada's desire to meet patient treatment needs and to build on its current product offering to physicians in the cardio-metabolic field, which already includes Lodalis, Tiazac XC and Glumetza.
Takeda Pharmaceuticals International Gmbh Announces Management Changes
Nov 1 14
Takeda Pharmaceutical Company Limited announced that Marc Princen joined Takeda Pharmaceuticals International GmbH as Corporate Officer and President of the EUCAN (Europe and Canada) Business Unit. In his new role, Princen will lead all business operations in Europe and Canada, and he will report directly to Christophe Weber, the President and Chief Operating Officer of Takeda. Princen brings more than 25 years of experience in the pharmaceutical industry including roles in a diverse
array of functions such as commercial, marketing, business development and management across the globe,
specifically, the United States, the Middle East and Africa, as well as several countries in Europe. Most
recently, Princen served as President of the Mid-Europe Region at Merck based in Switzerland, and before that
served as President and General Manager of Diversified Brands. Trevor Smith decided to leave Takeda and transition his professional home base to the United Kingdom after commuting to Zurich for several years. Smith will step down effective November 1, 2014 and will facilitate the transition of leadership until his departure from Takeda Pharmaceuticals International GmbH on March 31, 2015.
Apricus Biosciences Launches Erectile Dysfunction Treatment in UK
Jun 16 14
Apricus Biosciences has launched an on-demand treatment for erectile dysfunction called Vitaros. The company announced that Vitaros will be marketed in the United Kingdom by Takeda Pharmaceuticals International GmbH. The erectile dysfunction market in the United Kingdom was approximately $200 million in 2013 based on prescription sales, making it one of the larger erectile dysfunction markets in Europe. The European PDE-5 inhibitor market is approximately $1.5 billion as estimated by IMS Health, and analyst estimates for ex-US Vitaros sales are in the range of $300 million at peak. Apricus announced that it had received multiple commercial product orders of Vitaros from its partners and is currently manufacturing multiple product batches through its contract manufacturer in Canada to support launches in Europe. The company announced that commercialization of Vitaros has been fully licensed to these partners, with Apricus positioned to earn tiered double-digit royalties and more than $200 million in potential milestone payments.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|